We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SUPX:NASDAQSuperX AI Technology Limited Analysis

Data as of 2026-05-03 - not real-time

$7.68

Latest Price

8/10Risk

Risk Level: High

Executive Summary

SuperX AI Technology Limited (SUPX) trades at $7.68, roughly 71% above its DCF‑derived fair value of $4.48, while the 20‑day SMA ($8.24) sits just above price and the 200‑day SMA ($28.27) remains far higher, underscoring a strong bearish bias. The RSI of 43.5 suggests neutral momentum, and the MACD line (-0.325) is marginally above its signal (-0.327) with a tiny bullish histogram, offering no clear short‑term reversal. Volatility is extreme at 137% over the past 30 days and beta is elevated at 1.36, indicating the stock moves aggressively with the market. Support at $6.61 and resistance at $11.93 frame a narrow trading range, with current price near the lower bound, hinting at limited upside in the near term.
Fundamentally, SUPX posted a 130% revenue surge but operates at a negative operating margin (-2.0%) and zero net profit, with negative ROE (-1.58%) and a high price‑to‑book of 8.59. Cash ($17.21M) comfortably exceeds debt ($1.76M) yet operating cash flow is negative, and free cash flow is modestly positive. Recent material news highlights progress on a share‑repurchase program, signaling management confidence, and a strategic AI innovation centre partnership in Singapore, which could improve top‑line growth but does not yet offset the deep profitability gaps.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near support with limited upside
  • Neutral RSI and marginal bullish MACD signal
  • Extreme short‑term volatility

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Current price far above DCF fair value
  • Persistent negative operating margins and cash‑flow weakness
  • High beta and sector‑specific tech risk

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Potential upside from AI innovation centre partnership
  • Share‑repurchase program indicating management confidence
  • Fundamental profitability challenges remain unresolved

Key Metrics & Analysis

Financial Health

Revenue Growth130.40%
ROE-158.36%
ROA-25.03%
Debt/Equity8.87
P/B Ratio8.6
Op. Cash Flow$-8334584
Free Cash Flow$4.9M
Industry P/E38.5

Technical Analysis

TrendBearish
RSI43.5
Support$6.61
Resistance$11.93
MA 20$8.24
MA 50$9.37
MA 200$28.27
MACDBullish
VolumeStable
Fear & Greed Index91.09

Valuation

Fair Value$4.48
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.36
Volatility137.29%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.